Our clinical team published results of SIEGE trial on British Journal of Cancer
SIEGE trial is a randomised phase 2 study aiming to see whether sequential administration of nab-paclitaxel + gemcitabine 24 h apart could improve outcomes in patients with metastatic PDAC compared to standard delivery of 2 drugs on the same day.
Read the results